Live Biotherapeutics Drug Discovery Service for Multiple Sclerosis
Creative Biolabs offers a comprehensive range of biotechnology services and products. We are committed to safety, quality products, and excellent customer service while maintaining stability and consistency through the wisdom of innovation. We strive to create a win-win situation in every business relationship.
Overview
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by neuroinflammation, myelin degeneration, axon loss, and deterioration of the blood-brain barrier (BBB). The study found that in MS patients, the types and numbers of bacteria capable of producing large amounts of SCFA (Bacteroides, Parabacteroides, and Prevotella) were significantly reduced. The study of gut microbiota composition and neurodegenerative diseases, including MS, has emerged as a new area of research that can provide effective insights into the pathological mechanisms of disease.
Pathogenesis of MS
The pathogenesis of MS is multifactorial, among which immune system dysfunction has a variety of causes. The pathological features of MS are BBB disruption, demyelination, microglia activation, oligodendrocyte loss, astrocyte proliferation, and axonal degeneration. It posits that the pathogenesis of MS is mediated through an autoimmune response in which T and B cells become key players. An imbalance between the effector T cell and Tregs contributes to the proinflammatory state of MS. In the course of MS, reduced SCFAs can lead to impaired myelin regeneration, increased neuroinflammation, increased permeability of the BBB and intestinal barrier, oxidative stress, and aggravation of depressive symptoms.
Commensal and Probiotic Gut Bacterial Therapies
Probiotics include important microbial species that can regulate the immune response of host organisms healthily by producing antibacterial agents such as bacteriocins. Commensal microbiota is one component for induction of the development of MS. Many causes of diseases such as MS include dysbiosis in the intestinal microbiome. Gut-targeted microbial therapy is receiving increasing attention as an alternative or complementary treatment option for a variety of diseases, including MS. It is worth mentioning that microbiota modulation has been suggested as a possible approach to terminate neurodegenerative symptoms in MS patients. Lactobacillus plantarum and Lactobacillus paracasei attenuated CNS inflammation by inhibiting proinflammatory Th1 and Th17 cytokines in MS. The combined effect of Bifidobacterium animalis and Lactobacillus plantarum inhibits the progression of MS by regulating the infiltration of inflammatory T cells into the CNS. Oral administration of Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus fermentum, and Bifidobacterium bifidum probiotics inhibited gene expression of IL-8 and TNF-α in MS patients. With the appearance of probiotic therapy, Autoimmune diseases have entered a new term of treatment. probiotic therapy may be taken into consideration as a hopeful opportunity for MS treatment because of fewer side effects in comparison to current drug therapy.
Fig.1 Schematics of the role of the gut-brain axis in the course and treatment of multiple sclerosis.1
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Type/Similar Research
|
Research Article
|
Available Services
|
|
The microbiome as a therapeutic target for multiple sclerosis: can genetically engineered probiotics treat the disease?2
|
|
Creative Biolabs has grown, but one thing hasn't changed. We remain committed to providing on-time delivery and quality customer service. As a private company, we provide flexible and customized solutions for customers and suppliers. We welcome the opportunity to discuss how to help you achieve your goals and become a valuable part of your team. Please feel free to contact us for more information.
References
-
Preiningerova, Jana Lizrova, et al. "Multiple sclerosis and microbiome." Biomolecules 12.3 (2022): 433.
-
Kohl, Hannah M., Andrea R. Castillo, and Javier Ochoa-Repáraz. "The microbiome as a therapeutic target for multiple sclerosis: can genetically engineered probiotics treat the disease?." Diseases 8.3 (2020): 33.
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
